Eli Lilly and Company (LLY)
Lillys Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Lillys Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (81%) **Content type:** Clinical